ALZN Alzamend Neuro Quarterly EPS earnings growth

Corporate emblem and logo of alzamend.com (ALZN)

High failure risks in Alzheimer's therapy and a lack of revenue are putting pressure on quotes, as confirmed by the quarterly growth in earnings per share for Alzamend Neuro, Inc. (ALZN). The current 46.50 metric determines the status of the yield parameter. Diversified molecule supply chains guarantee production stability. Meanwhile, drug development relies on bioinformatic AI and automated laboratory complexes that eliminate routine labor.

alzamend.com (ALZN) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/16/2026

Alzamend Neuro (ALZN) - metric breakdowns and financial figures

- market value and analyst target forecast:
Summary company analysis:Alzamend Neuro Inc. - ALZN
Finished products of alzamend.com

For Alzamend Neuro, Inc. (ALZN), a leader in developing comprehensive treatments for Alzheimer's disease, the quarterly EPS trajectory serves as a tool for assessing the effectiveness of intellectual property capitalization. This metric measures the rate of change in net income per share, allowing investors to determine the company's ability to generate value amidst costly research protected by a patent portfolio through an analysis of the chart's dynamics.

Analysis of competing companies

BIIB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Bioscience Ltd) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Axsome Therapeutics, Inc. AXSM|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals Inc.)|XENE: Year-over-year net earnings per share trend for the last twelve months|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Supernus Pharmaceuticals (SUPN)|CPRX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Therapeutics)|HRMY: Quarterly EPS earnings growth|BHVN (Biohaven Pharmaceutical) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Amylyx|Quarterly EPS earnings growth Trevi Corp|Quarterly EPS earnings growth PRAX|AVXL (anavex.com) - Year-over-year earnings per one share growth for the last 12 months|CeriBell Inc - Year-over-year net earnings per share growth for the last 12 months|PRTA (Prothena Corporation plc) - Year-over-year net earnings per share trend for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|ANNX (Annexon Biosciences Inc.) - Year-over-year earnings per share growth for the last 12 months|OMER (omeros.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months NGNE|Year-over-year net earnings per share growth for the last 12 months ACIU|Quarterly EPS earnings growth Voyager Pharma|Year-over-year net earnings per share growth for the last 12 months NMRA (Neumora Therapeutics, Inc.)|SCLX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Tevogen Bio TVGN|Alpha Cognition Corp (ACOG) - Earnings per share growth in annualized terms for the last twelve months|CGTX: Year-over-year net earnings per share growth for the last 12 months|Inhibikase Therapeutics, Inc. - Year-over-year earnings per share growth rate for the last twelve months|SAVA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ASRT|COYA (coyatherapeutics.com) - Quarterly EPS earnings growth|Vistagen (VTGN) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OVID (Ovid Rx)|Year-over-year net earnings per share change for the last twelve months Acumen Pharmaceuticals, Inc.|Quarterly EPS earnings growth CRVO (CervoMed Corporation)|Year-over-year earnings per share growth rate for the last twelve months ATHE (Alterity Therapeutics Ltd)|Clene Nanomedicine - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year pepgen.com (PEPG)|JUNS: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months RLMD|ANVS (Annovis Bio Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Grace Therapeutics, Inc. (GRCE)|Quarterly EPS earnings growth AIFF|Year-over-year earnings per share growth rate for the last twelve months KLTO|Year-over-year earnings per share growth for the last twelve months neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings (RVPH) - Earnings per share growth in annualized terms for the last twelve months|MetaVia Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months NeurAxis Inc NRXS|HSDT (Helius Medical Technologies Inc.) - Year-over-year net earnings per share growth for the last 12 months|Passage Bio Inc. (PASG) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Neuphoria|Year-over-year net earnings per share growth for the last 12 months Minerva Neurosciences, Inc. (NERV)|Year-over-year earnings per share growth for the last twelve months Athira (ATHA)|Addex Therapeutics - Year-over-year earnings per share growth for the last 12 months|Cyclerion Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|PTIX (Protagenic Therapeutics) - Year-over-year net earnings per share trend for the last twelve months|Pasithea Therapeutics Corp - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Cortigent CRGT|ATXI (Avenue Therapeutics, Inc) - Year-over-year net earnings per share growth for the last 12 months|Brainstorm Cell Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months CARA|Earnings per share growth in annualized terms for the last twelve months chromocell.com CHRO|Year-over-year earnings per share growth for the last twelve months Eliem Therapeutics, Inc. (ELYM)|ITCI (Intra-Cellular Therapies, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth LBPH (Longboard Pharmaceuticals Inc)|Quarterly EPS earnings growth Marinus Pharma MRNS|nkgenbiotech.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months NeuroBo Pharmaceuticals, Inc.|Sage Therapeutics (SAGE) - Year-over-year earnings per share growth for the last twelve months|SNPX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Trevena, Inc|Vigil Neuroscience (VIGL) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth WENA|Quarterly EPS earnings growth cerevel.com (CERE)